This dataset provides data for new prescription drugs introduced to market in California with a Wholesale Acquisition Cost (WAC) that exceeds the Medicare Part D specialty drug cost threshold. Prescription drug manufacturers submit information to HCAI within a specified time period after a drug is introduced to market. Key data elements include the National Drug Code (NDC) administered by the FDA, a narrative description of marketing and pricing plans, and WAC, among other information. Manufacturers may withhold information that is not in the public domain. Note that prescription drug manufacturers are able to submit new drug reports for a prior quarter at any time. Therefore, the data set may include additional new drug report(s) from previous quarter(s).

There are two types of New Drug data sets: Monthly and Annual. The Monthly data sets include the data in completed reports submitted by manufacturers for calendar year 2025, as of November 7, 2025. The Annual data sets include data in completed reports submitted by manufacturers for the specified year. The data sets may include reports that do not meet the specified minimum thresholds for reporting.

The program regulations are available here: https://hcai.ca.gov/wp-content/uploads/2024/03/CTRx-Regulations-Text.pdf

The data format and file specifications are available here: https://hcai.ca.gov/wp-content/uploads/2024/03/Format-and-File-Specifications-version-2.0-ada.pdf

DATA NOTES: Due to recent changes in Excel capabilities, it is not recommended that you save these files to .csv format. If you do, when importing back into Excel the leading zeros in the NDC number column will be dropped. If you need to save it into a different format other than .xlsx it must be .txt

Submitted reports that are still under review by HCAI are not included in these files.

DATA UPDATES: Drug manufacturers may submit New Drug reports to HCAI for prescription drugs which were not initially reported when they were introduced to market. CTRx staff update the posted datasets monthly for current year data and as needed for previous years. Please check the 'Data last updated' date on each dataset page to ensure you are viewing the most current data.

The top U.S. pharmacy in 2024 by market share based on prescription drug revenue was CVS Health Corporation, followed by Walgreens Boots Alliance. CVS Health held over 25 percent of the prescription drug market revenue at that time. A significant increase in market share was reported for Cigna achieved through the acquisition of pharmacy benefit manager Express Scripts in August 2018. Before that, Cigna was mainly active in the insurance business and related products and services. CVS pharmaciesThe CVS Health Corporation is a health service company with locations all over the United States, Puerto Rico and Brazil. CVS Health comprises pharmacies, clinics and retail locations. According to recent estimates the number of CVS pharmacies has increased dramatically since 2005, however, with a downward tendency since 2021.Pharmaceutical and pharmacy marketThe U.S. has the largest single share of global pharmaceutical market revenues. The total number of prescriptions dispensed in the U.S. has increased in the last years, reaching around 6.7 billion medical prescriptions in 2022. Prescription drug expenditures have been increasing in value, while the share related to total U.S. health expenditures has remained stable in recent years. On the other hand, the pharmacy market recently saw some significant changes, especially with the growing impact of online pharmacies (mail-order pharmacies) worldwide.

This statistic depicts a projection for the total prescription drug revenue worldwide from 2023 to 2030. In 2025, the industry is expected to generate *** trillion U.S. dollars in prescription drug revenue worldwide. Revenues are projected to exceed *** trillion U.S. dollars by 2030. There is an increasing growth, especially, in sales of so-called orphan drugs for the treatment of rare diseases.

The global Prescription Drugs Market size was estimated at USD 1.16 trillion in 2024 and is anticipated to grow at a CAGR of 6.94% from 2025 to 2034.

Prescription Drugs Market size is expected to reach USD 2.47 Tn by 2032, from USD 1.34 Tn in 2025, exhibiting a CAGR of 9.1% during the forecast period

The U.S. Prescription Drugs Market size was valued at USD 461.33 USD Billion in 2023 and is projected to reach USD 755.46 USD Billion by 2032, exhibiting a CAGR of 7.3 % during the forecast period. Prescription drugs can only be purchased legally in America after the patient has been prescribed by a licensed pharmacist. It breaks it down into many types, which are Antibiotics, antidepressants, antipsychotics, Painkillers and many more. These drugs are recognized as being very effective in their workings and given in small dosages; the common populace cannot just buy these over the counter. Still, it includes FDA approval, the sources labelling and possible side effects which will have to be observed in the future. They are administered to control diseases that are chronic like high blood pressure, diabetes, depression, and a disease which is likely to be contracted. They have significant roles in the management of health and chronic illness and could potentially act as preventative measures against disease progress, and alleviate symptoms to improve patients’ lives. The benefits of the prescription are that it contains a therapeutic effect, results in minimizing hospital stays and leads to enhanced patient health in the long run. Recent developments include: June 2023: The U.S. FDA approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) manufactured by Boehringer Ingelheim International GmbH to improve blood sugar control in children ten years and older with type 2 diabetes., April 2022: Novartis AG announced the accelerated FDA approval of Vijoice (alpelisib) for treating adult and pediatric patients with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy., March 2021: Astellas Pharma Inc., announced the FDA approval of generic Myrbetriq (mirabegron) tablets for treating neurogenic detrusor overactivity (NDO) in pediatric patients aged three years and older.. Key drivers for this market are: Rising Approval of Orphan Drugs by Regulatory Agencies to Fuel Product Demand. Potential restraints include: High Costs of Specialty Prescription Drugs Compared to Over-the-Counter Drugs to Hamper Market Growth. Notable trends are: High Demand for Generic Drugs across the Country.

In 2024, the Japanese prescription drug market was valued at more than ** trillion Japanese yen, the historically highest value. The market size expanded by nearly four trillion yen throughout the past two decades.

Global Prescription Drugs market size 2021 was recorded $939.895 Billion whereas by the end of 2025 it will reach $1156 Billion. According to the author, by 2033 Prescription Drugs market size will become $1748.7. Prescription Drugs market will be growing at a CAGR of 5.31% during 2025 to 2033.

In 2024, Market Research Intellect valued the Prescription Drugs Market Report at 1.48 trillion, with expectations to reach 2.25 trillion by 2033 at a CAGR of 5.4%.Understand drivers of market demand, strategic innovations, and the role of top competitors.

Anti-Obesity Prescription Drugs Market Outlook

The global anti-obesity prescription drugs market is witnessing significant growth with a projected compound annual growth rate (CAGR) of 7.1% between 2024 and 2032. In 2023, the market size was valued at $11.5 billion, and it is expected to reach approximately $19.8 billion by 2032. This growth is primarily driven by the increasing prevalence of obesity worldwide, which is recognized as a leading cause of various chronic diseases such as diabetes, cardiovascular diseases, and certain types of cancer. The rising awareness about the health risks associated with obesity and the increasing inclination towards maintaining a healthy lifestyle are key factors contributing to the marketÂ’s expansion.

The growth of the anti-obesity prescription drugs market is fueled by several factors. Firstly, the rising prevalence of obesity has become a significant health concern globally. According to the World Health Organization, over 650 million adults were obese in 2021, and this number is continuously rising. This alarming trend has necessitated the development and approval of effective anti-obesity medications. Furthermore, increasing investment in research and development by pharmaceutical companies to innovate new drugs with fewer side effects and improved efficacy is another major driver of market growth. The regulatory approvals for new drugs and the pipeline of medications currently under development highlight the industry's commitment to addressing the obesity epidemic.

Another critical growth factor is the expanding geriatric population worldwide. As people age, they are more likely to experience metabolic changes that can lead to weight gain and obesity. The elderly population often requires medication management for various health conditions, including obesity, thereby driving demand for anti-obesity prescription drugs. Additionally, advancements in drug delivery systems and personalized medicine have tailored obesity treatments to individual genetic profiles and lifestyle factors, improving patient adherence and treatment outcomes. This personalized approach not only enhances efficacy but also reduces the side effects associated with anti-obesity drugs, further encouraging market growth.

Moreover, the surge in lifestyle-related disorders and sedentary lifestyles, particularly in urban areas, has spurred the demand for effective weight management solutions. The increasing consumption of high-calorie processed foods and reduced physical activity levels have led to a higher incidence of obesity, especially among the younger population. Public health initiatives and campaigns promoting weight management and the benefits of anti-obesity drugs are also crucial in raising awareness and boosting market growth. Consequently, healthcare professionals are increasingly prescribing anti-obesity drugs as part of comprehensive weight management programs, which include dietary changes and physical activity.

In the realm of pharmaceutical advancements, the Orlistat API has emerged as a pivotal component in the development of effective anti-obesity medications. Orlistat, a lipase inhibitor, works by preventing the absorption of dietary fats, thereby aiding in weight management. The API's role in formulating drugs that target obesity is crucial, as it offers a non-systemic approach to weight loss, minimizing potential side effects. As the demand for safer and more efficient anti-obesity drugs grows, the Orlistat API continues to be at the forefront of research and development efforts. Its integration into various drug formulations underscores its significance in the ongoing battle against obesity, providing healthcare professionals with a reliable option for patient treatment plans.

Regionally, North America holds the largest share of the anti-obesity prescription drugs market, driven by the high prevalence of obesity and the presence of advanced healthcare infrastructure. The United States, in particular, is a significant contributor to the regional market due to the high obesity rates among its population. Europe follows closely, with countries like the United Kingdom, Germany, and France exhibiting robust demand for these medications. The Asia Pacific region is expected to witness the highest growth rate, owing to the increasing awareness about obesity, rising disposable incomes, and improved access to healthcare facilities. In Latin America and the Middle East & Africa, the market is expanding gradually as awareness campaigns and health education initiatives gain momentum.

The Omega-3 Prescription Drugs Market Report is Segmented by Product Type (EPA-Only, EPA + DHA Ethyl Esters, and More), Indication (Severe Hypertriglyceridemia, Cardiovascular, and More), Dosage Form (Soft-Gel Capsules 1g, Soft-Gel Capsules 0. 5g, and More), Distribution Channel (Retail & Specialty Pharmacies, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

U.S. Prescription Drugs Market size was estimated at USD 27.83 billion in 2024 and is projected to grow at a CAGR of 9.3% from 2025 to 2034.

In 2019, original drugs accounted for the largest share in the domestic drug market in Japan with almost ** percent. Generics overtook the share of long-listed products for the first time in history, making up close to ** percent.

The North America Anti-Obesity Prescription Drugs report provides a detailed analysis of emerging investment pockets, highlighting current and future market trends. It offers strategic insights into capital flows and market shifts, guiding investors toward growth opportunities in key industry segments and regions.

Europe Prescription Drugs Market size was estimated at USD 301.16 billion in 2024 and is anticipated to grow at a CAGR of 6.9% from 2025 to 2034.

Technological advancements in the North America Omega 3 Prescription Drugs industry are shaping the future market landscape. The report evaluates innovation-driven growth and how emerging technologies are transforming industry practices, offering a comprehensive outlook on future opportunities and market potential.

This dataset provides data for new prescription drugs introduced to market in California with a Wholesale Acquisition Cost (WAC) that exceeds the Medicare Part D specialty drug cost threshold. Prescription drug manufacturers submit information to HCAI within a specified time period after a drug is introduced to market. Key data elements include the National Drug Code (NDC) administered by the FDA, a narrative description of marketing and pricing plans, and WAC, among other information. Manufacturers may withhold information that is not in the public domain. Note that prescription drug manufacturers are able to submit new drug reports for a prior quarter at any time. Therefore, the data set may include additional new drug report(s) from previous quarter(s). There are two types of New Drug data sets: Monthly and Annual. The Monthly data sets include the data in completed reports submitted by manufacturers for calendar year 2024, as of November 6, 2024. The Annual data sets include data in completed reports submitted by manufacturers for the specified year. The data sets may include reports that do not meet the specified minimum thresholds for reporting. The program regulations are available here: https://hcai.ca.gov/wp-content/uploads/2024/03/CTRx-Regulations-Text.pdf The data format and file specifications are available here: https://hcai.ca.gov/wp-content/uploads/2024/03/Format-and-File-Specifications-version-2.0-ada.pdf DATA NOTES: Due to recent changes in Excel capabilities, it is not recommended that you save these files to .csv format. If you do, when importing back into Excel the leading zeros in the NDC number column will be dropped. If you need to save it into a different format other than .xlsx it must be .txt

Prescription Drugs Market size was valued at USD 554 Billion in 2024 and is projected to reach USD 892 Billion by 2032, growing at a CAGR of 9.5% from 2026 to 2032.More people worldwide are living with conditions like diabetes, heart disease, and cancer. This rising burden increases the need for regular prescription medications. Patients rely on these drugs for long-term treatment and symptom management. Higher disease rates keep market demand steady.

The global Omega-3 Prescription Drugs Market size is projected to rise from USD 1.5 billion in 2024 to USD 3.36 billion by 2034, representing a CAGR above 8.4% for the 2025–2034 forecast period. Dominant industry players include GlaxoSmithKline, Pfizer, Amgen, Merck, Novartis, Teva Pharmaceutical, Mylan, OmegaBrite, Covis Pharma, Regeneron.

The Centers for Medicare and Medicaid Services estimate that prescription drug expenditure in the United States will reach around 460 billion U.S. dollars in 2024. This amount includes only retail drug spending, excluding nonretail. Estimations of drug spending can vary by investigating organization. For the U.S., among the most relevant drug spending calculations are provided by CMS, ASPE (Assistant Secretary for Planning and Evaluation), and pharmaceutical market researcher IQVIA. High drug prices in the U.S.The United States is the country with the highest total drug spending, and also with the highest per capita pharmaceuticals spending among developed countries. This is mostly connected to higher drug prices in the United States. For example, the price for the blockbuster drug Humira was almost three times higher in the United States than in Germany in 2017. But whereas in other countries, governments more or less directly control drug prices, the U.S. leaves drug pricing to market competition. As a consequence, the U.S. market is the most profitable for pharmaceutical companies. Where the money is spentNearly half of all Americans have taken at least one prescription medicine within the preceding month. The therapeutic areas where spending is the highest are ‘traditionally’ to be found among antidiabetics, oncologics, autoimmune, and respiratory diseases. Based on number of prescriptions filled, antihypertensives, pain reliever, and mental health drugs are the leading classes.